Active surveillance is a viable choice for African-American prostate cancer patients with low- or intermediate-risk disease, enabling long treatment-free periods and reasonable post-treatment outcomes, new Cleveland Clinic research shows.
Innovative diagnostic tools and treatments are refining management of prostate cancer, and helping clinicians and patients make better decisions.
Clinicians and patients are often concerned that biopsies miss occult high-grade prostate cancer. This study helps affirm that with a negative confirmatory biopsy, active surveillance is the right choice.
A recent Cleveland Clinic study revealed for the first time that the molecular features of a low-grade tumor as measured by genomic testing, rather than the amount of tumor present on biopsy, can identify which cancers should be treated and which are safe to watch.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
New evidence shows that men on active surveillance of prostate cancer can safely wait at least five years between surveillance biopsies. Study authors hope new findings increase appeal of disease monitoring and reduce patient and provider anxiety.
Molecular-based tests that predict prostate cancer’s aggressiveness have gotten a qualified endorsement from the National Comprehensive Cancer Network. The assays can be easily used to guide treatment decisions, says Cleveland Clinic’s Eric Klein, MD, boosting confidence in the choice of active surveillance for appropriate patients.
About half of men diagnosed with prostate cancer have low-risk disease. Here’s the evidence comparing active surveillance to curative therapy in this large group of patients…